OncoTherapy Science (TSE:4564) EV-to-FCF: (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4564 OncoTherapy Science Inc TSE:4564
51 GF Score
Price 円21.00
GF Value 円18.17
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, OncoTherapy Science's Enterprise Value is 円6,246.9 Mil. OncoTherapy Science's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.0 Mil. Therefore, OncoTherapy Science's EV-to-FCF for today is .

The historical rank and industry rank for OncoTherapy Science's EV-to-FCF or its related term are showing as below:

TSE:4564' s EV-to-FCF Range Over the Past 10 Years
Min: -6.34   Med: 0   Max: 0
Current: -6.34

TSE:4564's EV-to-FCF is ranked worse than
100% of 321 companies
in the Biotechnology industry
Industry Median: 18.66 vs TSE:4564: -6.34

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-25), OncoTherapy Science's stock price is 円21.00. OncoTherapy Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-2.360. Therefore, OncoTherapy Science's PE Ratio (TTM) for today is At Loss.


OncoTherapy Science  (TSE:4564) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

OncoTherapy Science's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=21.00/-2.360
=At Loss

OncoTherapy Science's share price for today is 円21.00.
OncoTherapy Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2.360.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


OncoTherapy Science EV-to-FCF Related Terms


OncoTherapy Science EV-to-FCF Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science EV-to-FCF Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.53 -9.92 -3.29 -8.31 -6.06

OncoTherapy Science Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -6.06 0.00

TSE:4564 vs VRTX, REGN, RVMD: EV-to-FCF Comparison

For the Biotechnology subindustry, OncoTherapy Science's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoTherapy Science EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's EV-to-FCF falls into.


TSE:4564
51GF Score
OncoTherapy Science Inc TSE:4564
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science EV-to-FCF Calculation

OncoTherapy Science's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6246.875/0
=

OncoTherapy Science's current Enterprise Value is 円6,246.9 Mil.
OncoTherapy Science's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is OncoTherapy Science (TSE:4564) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of 円21.00 is trading 15.6% above its estimated GF Value™ of 円18.17. GuruFocus considers OncoTherapy Science to be Modestly Overvalued.

Key valuation signals for TSE:4564:

  • EV-to-FCF:
  • GF Value™: 円18.17 vs. price of 円21.00 (15.6% above fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OncoTherapy Science Business Description

Other Exchanges 30O:Germany
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
51GF Score

Get the complete analysis for TSE:4564

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円21.00
Price
円18.17
GF Value